Skip to content

Search

Changes in thymic regulatory T-cell maturation from birth to puberty: Differences in atopic children

We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young...

Predominance of nontypeable haemophilus influenzae in children with otitis media

In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.

Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell tolerance

Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...

Trivalent influenza vaccine and febrile adverse events in australia, 2010: Clinical features and potential mechanisms

Increased numbers of children presenting with febrile adverse events following trivalent influenza vaccine (TIV) were noted in Australia in 2010.

TLR1/2 activation during Heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T cell responses providing

Leishmania (Viannia) parasites present particular challenges, as human and murine immune responses to infection are distinct from other Leishmania species

Immediate and Longer Term Immunogenicity and Safety of a Single Dose of the Combined Haemophilus influenzae Type

Hib-primed but MenC-naive toddlers (N = 433) were randomized to receive 1 dose of Hib-MenC-TT or separate Hib-TT and MenC-CRM197 vaccines.

Landmark Australian influenza collaboration finalist for Eureka Prize

Infectious disease researchers who used a decade of scientific evidence to advocate for a nationwide childhood influenza immunisation policy have earned a finalist position at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.

WA parents oblivious to true danger of the flu

Perth parents are underestimating the serious consequences of the flu, with only 19 per cent of children under five years of age currently immunized against the virus ahead of the peak winter flu season.